Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.81 |
| ▸ | HTR1A | P08908 | 2/20 | 0.78 |
| ▸ | HTR7 | P34969 | 2/20 | 0.78 |
| ▸ | HTR6 | P50406 | 2/20 | 0.78 |
| ▸ | ICMT | O60725 | 10/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18886985 | 0.94 | OPRM1 (0.71) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL12541297 | 0.93 | OPRM1 (0.84) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL19937128 | 0.93 | OPRM1 (0.84) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL12541565 | 0.90 | OPRM1 (0.67) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL18899397 | 0.90 | OPRM1 (1.00) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL12542194 | 0.90 | OPRM1 (1.00) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL18887022 | 0.90 | ICMT (0.67) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL18886901 | 0.89 | OPRM1 (0.65) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL19614667 | 0.89 | OPRM1 (0.82) | OPRM1HTR1AHTR7HTR6ICMT | |
| SCHEMBL12697599 | 0.89 | OPRM1 (0.65) | OPRM1HTR1AHTR7HTR6ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311222-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2018-11-01 | — | — | US | claimed |
| EP-3389657-A1 | METHODS OF TREATING HYPERALGESIA | Trevena, Inc. (US) | 2018-10-24 | — | — | EP | claimed |
| WO-2017106306-A1 | METHODS OF TREATING HYPERALGESIA | TREVENA, INC. (US) | 2017-06-22 | — | — | WO | claimed |
| EP-2688403-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | Trevena, Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| WO-2012129495-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | WO | claimed |
| US-11931350-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20220175747-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220175747-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | TREVENA, INC. | 2022-06-09 | — | — | US | disclosed |
| US-11077098-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077098-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210023043-A1 | Methods of Treating Hyperalgesia | TREVENA, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10588898-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-9044469-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8835488-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835488-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835488-B2 | Opioid receptor ligands and methods of using and making same | TREVENA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012129495-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175747-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885HTR1A 123/4885HTR7 150/4885 |
| US-20180311222-A1 | Opioid Receptor Ligands And Methods Of Using And Making Same | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885HTR1A 123/4885HTR7 150/4885 |
| US-11931350-B2 | Opioid receptor ligands and methods of using and making same | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885HTR1A 123/4885HTR7 150/4885 |
| US-10588898-B2 | Opioid receptor ligands and methods of using and making same | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885HTR1A 123/4885HTR7 150/4885 |
| US-11077098-B2 | Opioid receptor ligands and methods of using and making same | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885HTR1A 123/4885HTR7 150/4885 |
| US-20210023043-A1 | Methods of Treating Hyperalgesia | OPRL1, OPRK1, CHAT | OPRM1 35/4885HTR1A 313/4885HTR7 436/4885 |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | OPRL1, OPRK1, OPRM1 | OPRM1 3/4885HTR1A 123/4885HTR7 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.